Search companies

Live

Tuesday, 17 November 2026 · 583 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

EVE’s Libbo Patient Pathway Goes Live Ahead Of Planned Clinical Study

EVE: $0.014 -3.57% · MC: $5M

EVE Health Group says its patient access pathway for Libbo erectile dysfunction oral film is now operating end to end, with products supplied to patients ahead of full registration. The company is targeting pilot-study dosing in the December quarter, with results expected early next year to guide a proposed pivotal study; it reported closing cash of approximately $836,000 and no borrowings. Its director also disclosed an on-market purchase of shares, increasing indirect holdings.

Source announcements: 2026-10-30 13:05 to 2026-10-30 13:05 Sydney time
Story updated 2026-10-30 13:11 Sydney time
SourcesQuarterly Activities/Appendix 4C Cash Flow Report
Comments